Skip to main content

Table 2 Summary of febrile neutropenia incidence based on meta-analyses of trials of G-CSFs

From: Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

Treatment 1 Treatment 2 No of studies No of patients Relative risk of FN (95% CI) p-value I2 (heterogeneity)
Pegfilgrastim No primary G-CSF 5 2060 0.30 (0.14 to 0.65) p = 0.002 76%
Filgrastim No primary G-CSF 10 2183 0.57 (0.48 to 0.69) p < 0.00001 50%
Lenograstim No primary G-CSF 5 467 0.62 (0.44 to 0.88) p = 0.007 64%
Any G-CSF No primary G-CSF 20 4710 0.51 (0.41 to 0.62) p < 0.00001 74%
Pegfilgrastim Filgrastim 5 606 0.66 (0.44 to 0.98) p = 0.04 0%